'Here, we show in multiple cancer models that CXCR3+ Treg cells were increased in tumors compared with lymphoid tissues, exhibited an activated phenotype, and interacted preferentially with CXCL9-producing BATF3+ dendritic cells (DCs). Genetic ablation of CXCR3 in Treg cells disrupted DC1-Treg cell interactions and concomitantly increased DC-CD8+ T cell interactions.'

#Immunology #TumorImmunology #immunotherapy

https://www.cell.com/immunity/fulltext/S1074-7613(23)00260-1

When discussing the role of microbiome in modulating immune responses to tumours, I did not expect that to require the actual bacteria translocating to the tumour!

#TumorImmunology #medicine #immunity #immunology #melanoma
@cellpress
https://www.cell.com/cell/fulltext/S0092-8674(23)00271-4?dgcid=raven_jbs_etoc_email

Cool work from Michael Fischbach & collaborators: engineering skin bacteria to express tumoral antigens induces protective T cell responses - including at distal sites (in mice).
#immunology #immunotherapy #TumorImmunology

https://www.science.org/doi/10.1126/science.abp9563

Cool work from Michael Fischback & collaborators: engineering skin bacteria to express tumoral antigens induces protective T cell responses - including at distal sites (in mice).
#immunology #immunotherapy #TumorImmunology

https://www.science.org/doi/10.1126/science.abp9563

'Thus, identifying the subset of patients for whom public neoantigens are relevant targets is a major challenge. Nevertheless, the ability provided by the expansion of standard-of-care next-generation sequencing to screen patients affords the opportunity for off-the-shelf precision immunotherapies against public neoantigens that would be broadly applicable to many patients and would have tremendous advantages in scalability relative to targeting private neoantigens'
#Immunology #Immunotherapy #TumorImmunology

https://www.nature.com/articles/s43018-021-00210-y

'In this issue of Nature Medicine, Cascone et al.2share the latest results of their phase 2 platform trial, NEOSTAR, which suggest that the addition of CTLA-4 blockade to neoadjuvant anti-PD-1 plus chemotherapy may augment anti-tumor responses.'

#LungCancer #Immunology #TumorImmunology #immunotherapy #checkpointinhibitors

https://www.nature.com/articles/s41591-023-02246-2

"Here, we show that glycolysis drives STING signaling to facilitate DC-mediated antitumor immune responses. Tumor-infiltrating DCs exhibited elevated glycolysis, and blockade of glycolysis by DC-specific Ldha/Ldhb double deletion resulted in defective antitumor immunity."
#Immunology #TumorImmunology #Immunotherapy #Metabolism
#InnateImmunity

https://www.jci.org/articles/view/166031

STING maintains cells with metastatic potential in a dormant state in a mouse LUAD model.
#Immunology #TumorImmunology #CancerImmunity

https://www.nature.com/articles/s41586-023-05880-5

"Thus, we performed a comprehensive screen of TE-chimeric transcripts across 10,357 tumors, 675 cancer cell lines and 11,686 Genotype-Tissue Expression (GTEx) adult tissues, and evaluated these TE-chimeric candidates for tumor specificity, antigenic potential, proteomic validation, HLA presentation and membrane presence."
#TumorImmunology #immunology

https://www.nature.com/articles/s41588-023-01349-3

"The induction of cellular cytotoxicity requires that the NK cell contacts its target cell and establishes a lytic immunological synapse. Previous reports have revealed that membrane protrusions may be a component of immune synapses. Here, we explored whether changes in the topology of intratumoral NK cell membranes relate to the formation of lytic immunological synapses."

#Immunology #TumorImmunology

https://www.nature.com/articles/s41590-023-01462-9

"Here we show that metabolic conditioning of CD8+ effector T cells induces an oxidized cellular redox balance at least in part mediated by increased mitochondrial reactive oxygen species (ROS). This redox shift contributes to enhanced in vivo persistence and tumor clearance."

#Preprint #Immunology #metabolism #TumorImmunology

https://www.biorxiv.org/content/10.1101/2023.03.27.533229v1

This March the Dutch Society for Immunology (DSI/NVVI) host the NVVI Spring Meeting. We host inspiring talks on many topics in #immunology: #Infection, #Modeling, #Neuroscience, #Cytokines, #TumorImmunology.
It's a relatively small meeting, so you have plenty of opportunities to meet the speakers and other participants.

Early bird registration ends February 16th.

More information:
https://www.nvvi-dsi.nl/events2/sring-symposium-2023

#cartcells #cartcelltherapy #immunotherapy #genetherapy #IO #stemcell #stemcells #tumors #tumor #tumorimmunology #immunology

"Differing from its predecessor, ENLIGHT has been designed and evaluated with two real-world clinical scenarios in mind: personalized oncology, where one matches the best treatment to a patient based on a fixed decision threshold, and CTD, where the goal is to a priori exclude non-responding patients in the best possible manner. "

#immunotherapy #Immunology #TumorImmunology #Biomarker #PersonalisedMedicine

https://www.cell.com/med/fulltext/S2666-6340(22)00455-X#secsectitle0105

From a meeting report in #JournalImmunology:

"He (Jonathan Kagan) showed that old mice lose their naive CD8+ T cell repertoire, and the absence of CD8+ T cells in young mice reduces their survival rate. Protective immunity against cancer rises from CD4+ T cells in old mice, whereas CD8+ T cells are responsible for antitumor immunity in young mice."

#Immunotherapy #Immunology #TumorImmunology

https://journals.aai.org/jimmunol/article/209/12/2251/237566/Shedding-Light-on-Immunological-Research-in-Lyon

Looking to connect with anybody interested in #tumorimmunology and #invivobiology 👀🤓🐭🧬

In patients with advanced head and neck squamous cell carcinoma.
#Immunotherapy #TumorImmunology #Preprint

"Through a combination of single-cell analyses by mass cytometry (CyTOF), single-cell RNA-sequencing and TCR- sequencing (sc-RNA+TCR-seq), single cell RNA- and protein-sequencing (CITE-Seq), and multiplexed ion beam imaging (MIBI), we examined CD8+ T cells across tissues from patients treated with surgery as standard of care as well as patients treated with perioperative anti-PD-L1 ICB (atezolizumab)"

https://www.biorxiv.org/content/10.1101/2022.11.08.513062v1